Advertisement

Advertisement
Lung Cancer

Long-Term Outcomes With Single-Fraction vs Multifraction SABR for Pulmonary Oligometastases

As reported in the Journal of Clinical Oncology by Shankar Siva, PhD, and colleagues, long-term outcomes of the Trans Tasman Radiation Oncology Group (TROG)...

Leukemia

I Was Unprepared for a Diagnosis of Mantle Cell Lymphoma

The irony is not missed on me. In August 2022, 2 months before I was to start my tenure as President of the Union for International Cancer Control (UICC)...

Prostate Cancer

FDA Approves Flotufolastat Fluorine-18 Injection, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer

On May 30, the U.S. Food and Drug Administration (FDA) approved the optimized, high-affinity radiohybrid prostate-specific membrane antigen (PSMA)...


Advertisement
CNS Cancers

MGMT Promoter Methylation and Survival Outcomes in Low-Grade and Anaplastic Gliomas After Alkylating Chemotherapy

In a study reported in JAMA Oncology, Kinslow et al found that MGMT promoter methylation (mMGMT) was associated with improved survival outcomes...

Breast Cancer

Addition of First-Line Dalpiciclib to Letrozole or Anastrozole in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

In an interim analysis of a Chinese phase III trial (DAWNA-2) reported in The Lancet Oncology, Zhang et al found that the addition of the CDK4/6 inhibitor...

Advertisement




Leukemia
Lymphoma

Paolo Ghia, MD, PhD, on CLL/SLL and Ibrutinib Plus Venetoclax: A Primary Analysis of the CAPTIVATE Trial

Gynecologic Cancers
Pancreatic Cancer

Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers

An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). The findings suggest...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Hepatobiliary Cancer
Immunotherapy

Richard S. Finn, MD, on Treating Hepatocellular Carcinoma With Atezolizumab, Bevacizumab, and Sorafenib

Breast Cancer
Genomics/Genetics

OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer

One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...

Prostate Cancer

All-Cause Mortality Risk With Adjuvant vs Early Salvage Radiotherapy After Radical Prostatectomy

In a retrospective cohort study reported in the Journal of Clinical Oncology, Tilki et al found that adjuvant radiotherapy was associated with reduced risk for all-cause mortality vs early salvage radiotherapy among men at high risk for disease recurrence following radical prostatectomy. As stated ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lung Cancer
Immunotherapy

Patrick M. Forde, MD, on NSCLC: Nivolumab and Chemotherapy as Neoadjuvant Treatment

Breast Cancer
Genomics/Genetics

OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer

One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...